Podocyte autophagy pathway

The **podocyte autophagy pathway** is a highly conserved cellular mechanism essential for maintaining podocyte integrity and kidney filtration function. Podocytes have unusually high basal autophagic activity compared to other kidney cells, allowing them to survive stress, repair themselves, and prevent glomerular disease[1][3][4]. Regulation of podocyte autophagy involves key signaling proteins such as AMPK, mTOR, ULK1, Beclin1, and various ATG proteins[2][4][5][6]. Impairment of autophagy in podocytes leads to susceptibility to diverse kidney diseases, including diabetic nephropathy, focal segmental glomerulosclerosis, minimal change disease, and aging-related glomerular pathologies[2][4][6][3]. While the pathway itself may be an attractive target for therapeutic intervention, it is not a discrete molecular entity but a complex biological process comprising multiple proteins and signaling cascades. Drugs such as rapamycin, resveratrol, and sirtuin-1 modulators are being investigated for their ability to modulate autophagy and protect podocyte function in disease settings[4][2][7]. LC3-II and p62/SQSTM1 serve as key biomarkers to monitor autophagy activity experimentally[5][7]. Safety concerns in therapeutically targeting autophagy include risks of dysregulation that could affect cellular homeostasis and viability[4][6][7].

Other names

Podocyte autophagyautophagy in podocytesglomerular epithelial cell autophagy

mTOR inhibitors (e.g., rapamycin) restore autophagy and protect podocytes from injury. Lysosomal inhibitors block autophagosome degradation—used experimentally to measure autophagy. Sirtuin-1 agonists may activate autophagy via AMPK and mTOR pathways.